Chinese herbal medicine combined with conventional therapy for blood pressure variability in hypertension patients: A systematic review of randomized controlled trials

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Chen, Zhuo ^a   Wang, Liqiong ^a   Yang, Guoyan ^a   Xu, Hao ^b   Liu, Jianping ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b XIYUAN HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HERBACEOUS AGENT; PLACEBO;

ALTERNATIVE MEDICINE; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CHINESE HERB; CHINESE MEDICINE; DRUG EFFECT; DRUG SAFETY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

EID: 84930661992     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/582751     Document Type: Article

References (35)

1. P. M. Rothwell, S. C. Howard, E. Dolan et al., "Prognostic signifcance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension," The Lancet, vol. 375, no. 9718, pp. 895-905, 2010.
2. C. Tsioufs, I. Andrikou, C. Tomopoulos, D. Petras, A. Manolis, and C. Stefanadis, "Comparative prognostic role of nighttime blood pressure and nondipping profle on renal outcomes," American Journal of Nephrology, vol. 33, no. 3, pp. 277-288, 2011.
3. G. Parati, X. Liu, and J. E. Ochoa, "Clinical relevance of visit-to-visit blood pressure variability: impact on renal outcomes," Journal of Human Hypertension, vol. 28, pp. 403-409, 2014.
4. P. Muntner, D. Shimbo, M. Tonelli, K. Reynolds, D. K. Arnett, and S. Oparil, "The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: fndings from NHANES III, 1988 to 1994," Hypertension, vol. 57, no. 2, pp. 160-166, 2011.
5. G. Mancia, G. Parati, M. Hennig et al., "Relation between blood pressure variability and carotid artery damage in hypertension: Baseline data from the European Lacidipine Study on Atherosclerosis (ELSA)," Journal of Hypertension, vol. 19, no. 11, pp. 1981-1989, 2001.
6. A. J. Webb, U. Fischer, Z. Mehta, and P. M. Rothwell, "Efects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis," The Lancet, vol. 375, no. 9718, pp. 906-915, 2010.
7. ALLHAT Ofcers and Coordinators for the ALLHAT Collaborative Research Group, "The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)," The Journal of the American Medical Association, vol. 288, no. 23, pp. 2981-2997, 2002.
8. H.-H. Xie, F.-M. Shen, L.-P. Xu, P. Han, C.-Y. Miao, and D.-F. Su, "Reduction of blood pressure variability by combination therapy in spontaneously hypertensive rats," Journal of Hypertension, vol. 25, no. 11, pp. 2334-2344, 2007.
9. R. Sega, G. Corrao, M. Bombelli et al., "Blood pressure variability and organ damage in a general population: results from the PAMELA study," Hypertension, vol. 39, no. 2, pp. 710-714, 2002.
10. Z. Y. Zhao, Z. Y. Zhao, Y. Q. Wang, Z. H. Yan, J. Cui, and Y. Y. Li, "Quantitative study of circadian variations of ambulatory blood pressure in Chinese healthy, hypertensive, and diabetes subjects," Clinical and Experimental Hypertension, vol. 27, no. 2-3, pp. 187-194, 2005.
11. Y. Liu, J. C. Zhang, D. Z. Shi et al., "Fluctuant hypertension and platelet activation: current situations and control strategies with integrative medicine," Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 33, no. 7, pp. 869-872, 2013.
12. World Health Organization and International Society of Hypertension Writing Group, "2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension," Clinical and Experimental Hypertension, vol. 21, no. 5-6, pp. 1009-1060, 1999.
13. World Health Organization and International Society of Hypertension Writing Group, "2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension," Journal of Hypertension, vol. 21, no. 11, pp. 1983-1992, 2003.
14. Chinese Hypertension Prevention Guide Revision Committee, Chinese Hypertension Prevention Guide (2005 Revision), People's Health Publishing House, Beijing, China, 2006.
15. Chinese Hypertension Prevention Guide Revision Committee, "Chinese hypertension prevention guide 2010," Chinese Jounal of Hypertension, vol. 19, no. 8, pp. 701-708, 2011.
16. J. P. T. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0, The Cochrane Collaboration, Oxford, UK, 2011, http://handbook.cochrane.org/.
17. L. M. Pan, The Study of TCM Syndromes in Elderly Hypertensive Patients and Evaluation between Syndromes and Blood Pressure Variability and Treatment with TCM, China Academy of Chinese Medical Sciences, Beijing, China, 2012.
18. N. S. Ma, Study on Infuence of Qian Yang Yu Yin Granules on Blood Pressure Variability of the Patients with Hypertension, Nanjing University of Chinese Medicine, Nanjing, China, 2013.
19. L. Liang, Clinic Study on the Efects of Qin Dan Capsule in Treating Essential Hypertension Patients of "Liver Fire and Blood Stagnation", Shandong University, Jinan, China, 2007.
20. M. Shi, The Clinical Study of Sang Ji Wen Dan Decoction Treatment on Hypertension in Old Patients with Liver Yang Hyper Activity and Phlegm-Fire Syndrome, Nanjing University of Chinese Medicine, Nanjing, China, 2011.
21. F. Q. Wang, "Efcacy observation of Song ling xue mai kang combined with amlodipine in treating essential hypertension patients," Jilin Journal of Traditional Chinese Medicine, vol. 31, no. 2, pp. 149-150, 2011.
22. X. X. Kang and P. Fan, "The treatment of Xian Dan Tong Mai decoction in elderly hypertension patients," Shandong Journal of Traditional Chinese Medcine, vol. 32, no. 10, pp. 723-725, 2013.
23. L. Ma, J. He, and H. B. Li, "The impact of Xiang Tian Ma decoction on blood pressure variability in patients of defciency of Yin and internal dry," Xinjiang Journal of Traditional Chinese Medicine, vol. 31, no. 1, pp. 11-13, 2013.
24. Y. L. Li, "Efects of combined application of xuezhikang capsule with hypotensive drug on ambulatory blood pressure and blood pressure Variability," Guide of China Medicine, vol. 10, no. 6, pp. 41-43, 2012.
25. R. L. Ji and Q. H. Han, "Efcacy research on Yang xue qing nao particles in patients with hypertension," Chinese Journal of Integrative Medicine on Cardio-cerebrovascular Disease, vol. 9, no. 3, pp. 263-265, 2011.
26. W. N. Zhang, H. F. Huang, and X. Z. Tang, "Infuence of medicine leading to the liver channel in antihypertensive efcacy of amlodipine in the elderly hypertensive patients," in The Tenth TCM Academic Communication of Prevention and Treatment of Senile Diseases, Xianmen, China, 2012.
27. Z. Q. Yan, The Efect of Tiao Ping Kang Discus in Diurnal Rhythm and the Clinical Terapeutic Efect in Essential Hypertension Patients, Guangzhou University of Chinese Medicine, Guangzhou, China, 2008.
28. C. G. Liang, The Study on the "Gou Teng Si Wu Tang" Treating Level 1, 2 Elderly Hypertension, Shandong University of Chinese Medicine, Jinan, China, 2011.
29. J. Chen, The Intervention Efects of Qingxuan Granule on Endo-thelial Injury Induced by Infammatory Reaction of Hypertensive Patients, China Academy of Chinese Medical Sciences, Beijing, China, 2012.
30. X.-G. Sun, W.-K. Wu, and Z.-P. Lu, "Chinese integrative medicine: translation toward person-centered and balanced medicine," Chinese Journal of Integrative Medicine, vol. 18, no. 1, pp. 3-6, 2012.
31. S.-L. Chen, X.-Y. Liu, W.-M. Xu, W.-Y. Mei, and X.-L. Chen, "Clinical study of Western medicine combined with Chinese medicine based on syndrome diferentiation in the patients with polarized hypertension," Chinese Journal of Integrative Medicine, vol. 18, no. 10, pp. 746-751, 2012.
32. N. Freemantle, M. Calvert, J. Wood, J. Eastaugh, and C. Grifn, "Composite outcomes in randomized trials: greater precision but with greater uncertainty?" The Journal of the American Medical Association, vol. 289, no. 19, pp. 2554-2559, 2003.
33. L. L. Kjaergard, J. Villumsen, and C. Gluud, "Reported method-ologic quality and discrepancies between large and small randomized trials in meta-analyses," Annals of Internal Medicine, vol. 135, no. 11, pp. 982-989, 2001.
34. K. F. Schulz, D. G. Altman, and D. Moher, "CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials," Annals of Internal Medicine, vol. 152, no. 11, pp. 726-732, 2010.
35. J. J. Gagnier, H. Boon, P. Rochon, D. Moher, J. Barnes, and C. Bombardier, "Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement," Annals of Internal Medicine, vol. 144, no. 5, pp. 364-367, 2006.